Manhattan Scientifics

 

"During the nasdaq bubble in year 2000, Manhattan Scientifics had a market capitalization approaching $900 million, about 60 times the company’s present market cap, despite the fact that the companies intrinsic value is worth many times more today than it was in year 2000."

Albuquerque October 15, 2010 - Manhattan Scientififics announced that at today’s historic press conference introducing the use of the first FDA-approved dental implant made with nanotitanium, the company will sign a letter of intent with NanoMet, the Russian enterprise that helped create nanotitanium (titanium on steroids) to participate in the distribution of dental implants in Russia. The dental implants will be manufactured by Basic Dental Inc., the Albuquerque-based manufacturer of America’s first nanotitanium dental implants, which possess the ability to bond more quickly to human bone and promote faster healing.

Manhattan Scientifics Founder Marvin Maslow said “We’re living longer and we need new parts. We’re very excited about this agreement, especially considering the tremendous potential of the medical prosthetics market. The bottom line is that dental implants are just the tip of the iceberg of what is estimated to be a $20 billion annual market.”

 

aktueller kurs 0,111 USD, ein plus von knapp 20% allein heute - und keiner hier hat eine meinung?

charttechnisch scheint der kursverlauf ein W bilden zu wollen.

sollte sich - nach langer Durststrecke - bei MHTX endlich was bewegen?

... es ist eine klassische Bullenfalle.

Immerhin haben sich seit den Tiefstständen die Umsätze vervielfacht.  

... ist die angegebene Website falsch. Sie lautet:
mhtx.com/

NEW YORK--Manhattan Scientifics Inc., a principal & major shareholder of Imagion Biosystems Ltd. (IBX.AX) announces IMAGION’S initiation of manufacturing medical devices and pharma products to be used in first human clinical studies of very early cancer detection as approved by the FDA.
The primary operational focus for Imagion’s past quarter has been on ensuring the readiness of its contract-manufacturing partners to begin the manufacturing of the nanoparticle formulation to be used in the study. Imagion is pleased to report it has purchased equipment and supplies and has completed the necessary vendor qualifications and audits to confirm compliance with GMP (Good Manufacturing Practice), required for the manufacturing of medical devices and pharmaceutical products used in human clinical studies.
Marvin Maslow, Chairman of MHTX said, “MHTX invested millions of dollars to commercialize Edward Flynn’s work to create a reliable and inexpensive cancer diagnostic, with a stated goal to identify pre symptomatic cancers well before they metastasize in humans.“

Der Handelsplatz:  
                                       www.otcmarkets.com/stock/MHTX/overview

entweder es ist doch eine Bullenfalle,
oder es wird das Wunder von Manhattan
oder ...  

… in einem halben Jahr sind wir klüger. Oder auch nicht.